Verici Dx raises £8.5 million and launches a retail offer to raise up to a further £250,000
October 2026
Verici Dx plc is an LSE AIM listed developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.
Placing and launch of retail offer
On 9 October the Company announced that it has conditionally raised gross proceeds of £8.5 million by way of a placing of 4,250,000,000 Placing Shares with existing and new investors at the Issue Price of 0.20 pence per Placing Share.
The Company further announced a retail offer via the Winterflood Retail Access Platform to raise up to £250,000 through the issue of new ordinary shares of £0.001 each in the capital of the Company. Under the Retail Offer up to 125,000,000 new Ordinary Shares will be made available at a price of £0.002 per share.
Having helped Verici Dx with the production of their admission document when they floated on AIM in November 2020 and with the production of their annual reports since, the Perivan shareholder communications team was delighted to work with Singer Capital Markets who acted as Nominated adviser and Shoosmiths who acted as legal adviser on the shareholder documentation which was successfully completed and posted to qualifying shareholders on 9 October 2026.
Perivan specialises in producing and publishing financial documents relating to shareholder and investor communications for quoted companies and is a market leader in the production of documentation relating to corporate finance transactions.